ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of “Buy” from Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have received an average rating of “Buy” from the nine research firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $78.88.

A number of equities analysts have commented on the stock. Truist Financial lifted their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a “hold” rating in a research note on Monday, April 21st. Guggenheim reissued a “buy” rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. Wall Street Zen cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, April 24th. Finally, HC Wainwright began coverage on shares of ANI Pharmaceuticals in a research note on Thursday, July 10th. They set a “buy” rating and a $84.00 price target for the company.

Insider Activity

In related news, SVP Ori Gutwerg sold 881 shares of the business’s stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total transaction of $52,921.67. Following the completion of the transaction, the senior vice president owned 89,897 shares in the company, valued at $5,400,112.79. The trade was a 0.97% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Meredith Cook sold 400 shares of the business’s stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $64.88, for a total transaction of $25,952.00. Following the sale, the vice president directly owned 78,945 shares in the company, valued at approximately $5,121,951.60. This represents a 0.50% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,681 shares of company stock worth $345,222. 11.10% of the stock is currently owned by corporate insiders.

Institutional Trading of ANI Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Principal Financial Group Inc. increased its holdings in ANI Pharmaceuticals by 68.3% in the 1st quarter. Principal Financial Group Inc. now owns 157,798 shares of the specialty pharmaceutical company’s stock valued at $10,565,000 after purchasing an additional 64,021 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in ANI Pharmaceuticals by 14.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company’s stock worth $854,000 after purchasing an additional 1,972 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in ANI Pharmaceuticals by 53.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 8,949 shares of the specialty pharmaceutical company’s stock worth $599,000 after purchasing an additional 3,112 shares in the last quarter. GAMMA Investing LLC lifted its stake in ANI Pharmaceuticals by 163.8% during the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company’s stock worth $95,000 after purchasing an additional 881 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its stake in ANI Pharmaceuticals by 6.6% during the fourth quarter. Victory Capital Management Inc. now owns 13,777 shares of the specialty pharmaceutical company’s stock worth $762,000 after purchasing an additional 858 shares in the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Stock Down 2.6%

Shares of ANIP stock opened at $66.30 on Tuesday. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -52.20 and a beta of 0.57. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $77.00. The company’s fifty day moving average price is $62.88 and its 200-day moving average price is $62.70. The company has a debt-to-equity ratio of 1.46, a current ratio of 2.66 and a quick ratio of 1.98.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.37 by $0.33. The firm had revenue of $197.12 million for the quarter, compared to the consensus estimate of $179.75 million. ANI Pharmaceuticals had a negative net margin of 3.12% and a positive return on equity of 21.35%. The company’s revenue was up 43.4% on a year-over-year basis. During the same period last year, the firm earned $0.82 EPS. Sell-side analysts expect that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.